Canakinumab Treatment: An In-Depth Guide
Understanding Canakinumab
Canakinumab is a fully human monoclonal antibody that targets interleukin-1β (IL-1β). It has anti-inflammatory effects and has been approved for the treatment of various conditions, including: * Cryopyrin-associated periodic syndromes (CAPS) * Familial Mediterranean Fever (FMF) * Tumor Necrosis Factor (TNF) inhibitor-inadequate response in Rheumatoid Arthritis (RA)
Administration of Canakinumab
Canakinumab is administered as a subcutaneous injection every 8 weeks.
Instructions for Healthcare Professionals
* Refer to the prescribing information for detailed administration guidelines. * Ensure proper aseptic technique. * Inject subcutaneously into the abdomen or thigh. * Rotate injection sites to minimize discomfort.
Information for Patients
* Inform your healthcare provider about all medications you are taking, including prescription and over-the-counter drugs, and herbal supplements. * Notify your healthcare provider if you have any allergies, especially to canakinumab or any of its ingredients. * Follow your healthcare provider's instructions for proper administration and storage of canakinumab. * Report any side effects to your healthcare provider promptly.
Additional Resources
* Patient and healthcare professional fact sheets are available online: * [Patient Merkblätter](https://example.com/patient-merkblaetter) * [Healthcare Professional Merkblätter](https://example.com/healthcare-professional-merkblaetter)
Comments